Isogenica Announces Research Collaboration Agreement with GE Healthcare
Complete the form below to unlock access to ALL audio articles.
Isogenica Ltd and GE Healthcare have announced that they have entered into a research collabortion for the discovery of in vivo diagnostic and medical imaging compounds.
Under the terms of the agreement, Isogenica will use its CIS display technology to select peptide ligands to two undisclosed disease targets to be identified by GE Healthcare.
GE Healthcare will then have an option to advance to clinical development any imaging agent resulting from the collaboration; the collaboration will be supervised by a Steering Committee consisting representatives from both companies.
Isogenica’s CIS display technology is designed to provide an effective means of identifying peptides that bind with high affinity and specificity to any given molecular target.
The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.
"We look forward to building a strong and fruitful relationship with GE Healthcare and in assisting them with their in vivo diagnostic and medical imaging activities," said Dr. Kevin FitzGerald, Isogenica’s CEO.
"We believe that because of their rapid in vivo distribution along with their prompt serum clearance, peptides, and especially those discovered and matured using Isogenica’s CIS display technology, represent a very rich source of compounds for in vivo diagnostic and medical imaging applications."
"Isogenica’s proprietary technology may allow us to identify novel imaging agents for the early diagnosis of disease, thereby allowing physicians to prescribe the right dose of the right drug at the right time to the right patient," said Dr. Marivi Mendizabal, Head of Research in GE Healthcare, Medical Diagnostics.
